Literature DB >> 19816886

The possible macroeconomic impact on the UK of an influenza pandemic.

Marcus R Keogh-Brown1, Simon Wren-Lewis, W John Edmunds, Philippe Beutels, Richard D Smith.   

Abstract

Little is known about the possible impact of an influenza pandemic on a nation's economy. We applied the UK macroeconomic model 'COMPACT' to epidemiological data on previous UK influenza pandemics, and extrapolated a sensitivity analysis to cover more extreme disease scenarios. Analysis suggests that the economic impact of a repeat of the 1957 or 1968 pandemics, allowing for school closures, would be short-lived, constituting a loss of 3.35 and 0.58% of GDP in the first pandemic quarter and year, respectively. A more severe scenario (with more than 1% of the population dying) could yield impacts of 21 and 4.5%, respectively. The economic shockwave would be gravest when absenteeism (through school closures) increases beyond a few weeks, creating policy repercussions for influenza pandemic planning as the most severe economic impact is due to policies to contain the pandemic rather than the pandemic itself.Accounting for changes in consumption patterns made in an attempt to avoid infection worsens the potential impact. Our mild disease scenario then shows first quarter/first year reductions in GDP of 9.5/2.5%, compared with our severe scenario reductions of 29.5/6%. These results clearly indicate the significance of behavioural change over disease parameters.
Copyright © 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 19816886     DOI: 10.1002/hec.1554

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  33 in total

1.  Macroeconomic impact of pandemic influenza and associated policies in Thailand, South Africa and Uganda.

Authors:  Richard D Smith; Marcus R Keogh-Brown
Journal:  Influenza Other Respir Viruses       Date:  2013-09       Impact factor: 4.380

2.  Microsimulation of financial impact of demand surge on hospitals: the H1N1 influenza pandemic of fall 2009.

Authors:  Sabina Braithwaite; Bernard Friedman; Ryan Mutter; Michael Handrigan
Journal:  Health Serv Res       Date:  2013-02-10       Impact factor: 3.402

3.  Optimal Timing of Non-Pharmaceutical Interventions During an Epidemic.

Authors:  Nick F D Huberts; Jacco J J Thijssen
Journal:  Eur J Oper Res       Date:  2022-06-22       Impact factor: 6.363

4.  Cost-effectiveness of pharmaceutical-based pandemic influenza mitigation strategies.

Authors:  Anthony T Newall; James G Wood; Noemie Oudin; C Raina MacIntyre
Journal:  Emerg Infect Dis       Date:  2010-02       Impact factor: 6.883

5.  Fighting a war without weapons? Lessons from the COVID-19 outbreak.

Authors:  Evangelos Vasileiou
Journal:  World Med Health Policy       Date:  2021-04-08

6.  Simulating school closure policies for cost effective pandemic decision making.

Authors:  Ozgur M Araz; Paul Damien; David A Paltiel; Sean Burke; Bryce van de Geijn; Alison Galvani; Lauren Ancel Meyers
Journal:  BMC Public Health       Date:  2012-06-18       Impact factor: 3.295

7.  Economic considerations for social distancing and behavioral based policies during an epidemic.

Authors:  Eli P Fenichel
Journal:  J Health Econ       Date:  2013-01-26       Impact factor: 3.804

8.  The economy-wide impact of pandemic influenza on the UK: a computable general equilibrium modelling experiment.

Authors:  Richard D Smith; Marcus R Keogh-Brown; Tony Barnett; Joyce Tait
Journal:  BMJ       Date:  2009-11-19

9.  Estimating the impact of school closure on social mixing behaviour and the transmission of close contact infections in eight European countries.

Authors:  Niel Hens; Girma Minalu Ayele; Nele Goeyvaerts; Marc Aerts; Joel Mossong; John W Edmunds; Philippe Beutels
Journal:  BMC Infect Dis       Date:  2009-11-27       Impact factor: 3.090

10.  Skip the trip: air travelers' behavioral responses to pandemic influenza.

Authors:  Eli P Fenichel; Nicolai V Kuminoff; Gerardo Chowell
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.